心血管疾病

Going beyond standard lipid panels to assess lipoprotein, apolipoprotein, inflammatory, metabolic, and genetic risk factors may provide deeper insights into the residual risk of your patients.

\r\n

Advanced biomarkers have been shown to help identify residual risk and have been adopted by several practice guidelines and professional societies.^2,3 With deeper insights, you can take further action to help reduce your patients’ risk for adverse cardiovascular events. 

\r\n","@type":"corporate/components/text"}}" id="text-f24e71983b" class="cmp-text">

超越標準脂質麵板以評估脂蛋白，載脂蛋白，炎症，代謝和遺傳危險因素可能會對您患者的殘餘風險提供更深入的見解。

已顯示先進的生物標誌物有助於識別剩餘風險，並通過幾種實踐指南和專業社會采用。^2,3隨著深度洞察力，您可以采取進一步的行動來幫助減少患者對不良心血管事件的風險。

Nearly 50% of all heart attacks and strokes occur in patients with “normal” cholesterol levels. Recent evidence goes beyond lipids to suggest that inflammation within the artery wall is the primary contributor to this residual risk for heart attack and stroke. Inflammation contributes to both vulnerable plaque formation and to plaque rupture.⁴

\r\n

The beginnings of CVD are rooted in injury to the arterial wall. Risk factors like smoking, hypertension, and diabetes injure the arterial wall, making it more susceptible to penetration and accumulation of excess lipids.

\r\n

The inflammatory response to injury contributes to the progression of plaque development and is a key factor in the formation of vulnerable plaque and plaque rupture, which may cause a heart attack or stroke. 

\r\n","@type":"corporate/components/text"}}" id="text-c5232f1d50" class="cmp-text">

近50％的心髒病發作和中風患者發生“正常”膽固醇水平。最近的證據超越了脂質，表明動脈牆內的炎症是心髒病發作和中風的這種殘留風險的主要因素。炎症有助於脆弱的斑塊形成和斑塊破裂。^4.

CVD的開始根植於動脈壁的傷害。危險因素等吸煙，高血壓和糖尿病損傷動脈牆，使其更容易受到過度脂質的滲透和積累。

對損傷的炎症反應有助於斑塊發展的進展，是脆弱斑塊和斑塊破裂形成的關鍵因素，可能導致心髒病發作或中風。

Patients who have metabolic syndrome are at higher risk of multiple chronic conditions, including diabetes, coronary heart disease, and cancer, as well as stroke. Metabolic syndrome has become increasingly common: its prevalence has risen in every sociodemographic group, and today it is estimated that more than a third of adults in the United States have metabolic risk.⁵

\r\n","@type":"corporate/components/text"}}" id="text-b7bf5e4364" class="cmp-text">

具有代謝綜合征的患者具有較高的慢性病症的風險較高，包括糖尿病，冠心病和癌症以及中風。代謝綜合征變得越來越普遍：它的普遍存在率在每個社會階段群體中程度上升，今天據估計，美國超過三分之一的成年人具有代謝風險。^5.

The recently updated ACCF/AHA guidelines for the management of heart failure recommend BNP or NT-proBNP biomarker testing followed by early intervention as an aid for prevention. Quest offers advanced biomarker testing to help prevent heart failure in your at-risk patients.

\r\n","@type":"corporate/components/text"}}" id="text-1f62124d38" class="cmp-text">

最近更新的ACCF / AHA用於管理心力衰竭的準則推薦BNP或NT-ProbnP生物標誌物測試，然後提前幹預作為預防援助。任務提供先進的生物標誌物測試，以幫助防止患有風險患者的心力衰竭。

In many patients, the risk of CVD may be attributed to nonlipid factors, including genetic polymorphisms and mutations. Quest offers cardiogenetic testing to aid in early diagnosis and earlier treatment for affected patients as well as family members.

\r\n","@type":"corporate/components/text"}}" id="text-94ccfb5997" class="cmp-text">

在許多患者中，CVD的風險可能歸因於非脂質因子，包括遺傳多態性和突變。任務提供型心肌試驗，幫助受影響患者的早期診斷和早期治療以及家庭成員。